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Effects of amlodipine and lisinopril on intima–media
thickness in previously untreated, elderly hypertensive
patients (the ELVERA trial)
Willem F. Terpstraa,e, Johan F. Maya,e, Andries J. Smitb,e, Pieter A. de Graeffc,e,
Betty Meyboom-de Jongd,e and Harry J.G.M. Crijnsa
Objective To compare the effects of the calcium channel
blocker amlodipine and the angiotensin-converting
enzyme inhibitor lisinopril on intima–media thickness (IMT)
in elderly, previously untreated hypertensive individuals.
Design A double-blind randomized parallel-group trial (the
ELVERA trial).
Patients The study population comprised 166 newly
diagnosed hypertensive individuals (aged 60–75 years)
with diastolic blood pressure between 95 and 115 mmHg
or systolic blood pressure between 160 and 220 mmHg, or
both.
Intervention Patients were allocated randomly to groups
to receive amlodipine 5–10 mg or lisinopril 10–20 mg for
2 years.
Main outcome measures Before and after 1 and 2 years
of treatment, IMT was measured in three carotid and two
femoral arterial sites by B-mode ultrasound. The primary
endpoint was the change from baseline of the combined
mean maximum far wall IMT of carotid and femoral
arteries, evaluated by repeated measurement analysis of
the treatment effect in an intention-to-treat analysis.
Results After 2 years of treatment, amlodipine decreased
IMT by 0.089 mm [95% confidence interval (CI) 0.144 to
0.037]. Lisinopril decreased IMT by 0.065 mm (95% CI
0.124 to 0.010). No differences between the two drugs
were found (P 0.18). Both treatment regimens achieved
the greatest reduction of IMT after 1 year, with a slight
increase after the second year, whereas the reduction in
blood pressure was maintained. Comparing the carotid
and femoral arteries, a significant treatment difference in
the change from baseline in favour of amlodipine was
observed in the IMT of the elastic common carotid artery
(P < 0.05). The effects of the two drugs on the muscular
common femoral artery were not different.
Conclusion In a long-term study, amlodipine and lisinopril
reduce IMT to a similar extent in newly diagnosed elderly
hypertensive patients. It is suggested that the two drugs
have different effects on arteries that are not prone to
atherosclerosis. J Hypertens 22:1309–1316 & 2004
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Introduction
Antihypertensive treatment decreases the incidence of
hypertension-related cardiovascular events [1–3]. How-
ever, insufficient data are available as to how this
treatment affects the cardiovascular damage underlying
these events [4], and the clinical effects of antihyper-
tensive treatment on the development of atherosclero-
sis are also mainly unknown [4]. More trials measuring
the effects of antihypertensive drugs on vascular wall
characteristics are needed [5].
Increase in intima–media thickness (IMT) is regarded
as an early sign of atherosclerosis [6]. Progression of
IMT has been associated with the presence of cardio-
vascular risk factors such as age, serum low-density
lipoprotein cholesterol, hypertension and smoking [7–
9], in addition to cardiovascular morbidity [10,11].
Reduction of cardiovascular risk factors reduces IMT
progression [12–14]. IMT can be measured with high-
resolution B-mode ultrasound, which has been shown
to be a validated, sensitive and reproducible non-
invasive endpoint assessment of the status of athero-
sclerosis and prediction of future cardiovascular disease
[15].
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An important question is whether various antihyperten-
sive drugs affect atherosclerosis to a similar extent.
The probability that certain antihypertensive drugs, in
particular calcium channel blockers and angiotensin-
converting enzyme (ACE) inhibitors, exert an anti-
atherosclerotic action that is at least partly independent
of the blood pressure-decreasing effect is supported by
evidence obtained from studies using experimental
models of the development of atherosclerosis [16]. This
suggests the possibility of differences in effects on
IMT in the clinical situation.
The Effects of Amlodipine and Lisinopril on Left
Ventricular Mass and Diastolic Function (E/A Ratio)
(ELVERA) trial was a prospective, randomized, dou-
ble-blind, single-centre trial comparing the 2-year treat-
ment effects of amlodipine and lisinopril monotherapy
on left ventricular mass in elderly, previously untreated
hypertensive individuals. Previously, we found that
treatment with amlodipine and lisinopril resulted in
equivalent reduction of left ventricular mass in these
patients [17]. We now report the findings from the
ELVERA trial concerning the effect of both drugs on
carotid and femoral arterial wall thickness with respect
to detecting clinical differences in vascular remodelling
in previously untreated, elderly hypertensive patients.
Methods
Patients
Patients with previously untreated mild to moderate
hypertension were enrolled from a population survey
performed in the north of the Netherlands in two rural
municipalities. Systolic (SBP) and diastolic (DBP)
blood pressures were measured with the patient in the
sitting position after 5 min of rest. If a difference in
blood pressure was detected between the two arms
(.5 mmHg for DBP and .10 mmHg for SBP), the arm
with the highest blood pressure was used for future
measurements; otherwise, the right arm was used.
Patients were considered to be hypertensive when
four measurements of DBP were between 95 and
115 mmHg or SBP was between 160 and 220 mmHg
(or both), derived from several measurements made on
three occasions over a period of 4 weeks. Patients with
hypertension and aged between 60 and 75 years were
selected for the study and advised to restrict their salt
intake (low-salt diet). After another period of 4 weeks,
blood pressure was measured for the fifth time and
hypertensive patients who met the inclusion criteria
received placebo treatment for 2 weeks. If blood pres-
sure remained stable during this run-in period, the
patients were randomly assigned to the double-blind
treatment phase, to receive 5 mg amlodipine or 10 mg
lisinopril. After 6 weeks of active treatment the dosage
was increased to 10 mg amlodipine and 20 mg lisinopril.
Patients who experienced adverse effects with the
higher dose had their dose adjusted to 5 mg amlodipine
or 10 mg lisinopril.
Exclusion criteria for the study were: office blood
pressure .220/115 mmHg; unstable blood pressure
after the period of placebo treatment, defined as
differences in DBP or SBP readings before placebo
treatment of .10 mmHg or .20 mmHg, respectively;
secondary hypertension of any aetiology; angina pec-
toris; manifest coronary artery disease; current or recent
history of congestive heart failure; haemodynamically
significant valvular heart disease; cardiac arrhythmia;
renal insufficiency; insulin-dependent diabetes melli-
tus. Written informed consent was obtained from all
participants and the study was approved by the medical
ethics committee of the University Hospital of Gronin-
gen. Patient compliance was assessed by counting
returned tablets at the various visits.
Blood pressure measurements
Office blood pressure and heart rate were measured
with the patient in the sitting position after 5 min of
rest twice at every visit (6, 8, 18, 35, 52, 68, 85 and
104 weeks after the start of active treatment) with a
2 min interval between the measurements. In addition,
blood pressure and heart rate were measured with the
patient in the standing position after another 2 min.
The mean of two sitting blood pressure measurements
was calculated. SBP and DBP were recorded at Korotk-
off phase I and V to the nearest 2 mmHg.
Intima-media thickness measurements
Ultrasound measurements were performed by two
experienced and certified sonographers at baseline and
after 1 and 2 years of active treatment. An Acuson 128
XP ultrasound system (Acuson Corp., Mountain View,
California, USA) with a 7 MHz linear array transducer
was used. Three arterial wall segments of both carotid
arteries and two segments of both femoral arteries were
measured with the patient supine. For the carotid
arteries, the far wall segments of the common carotid
artery, carotid bulb and internal carotid were imaged
from a fixed lateral transducer position. For the femoral
arteries, the far wall segments of the common and the
superficial femoral arterial walls were imaged from a
fixed anterior transducer position. All images were
saved on S-VHS tape and analysed off-line throughout
the study by an analyst who was unaware of the
patients’ characteristics.
The primary endpoint of the study was the change in
combined mean maximum far wall IMT of 10 segments
of the carotid and femoral artery after 2 years of
treatment. The combined far wall IMT of the carotid
and femoral arteries was taken because atherosclerosis
is regarded as a generalized disease. The secondary
endpoints were the changes in maximum far wall IMT
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of the common carotid artery, a mainly elastic artery,
and the common femoral artery, a mainly muscular
artery. From studies on repeatability, the error of
variation in measurement in the population studied was
calculated as 0.03 mm for the primary, combined car-
otid and femoral far wall IMT, endpoint.
Left ventricular mass measurements
All echocardiographic examinations were performed by
one observer, who was blinded to the treatment regi-
men and blood pressure measurements. An Acuson XP-
10 echocardiograph (Acuson Corp.) with a 2.5–4.0 MHz
transducer was used. Three measurements were made
of end-diastolic left ventricular posterior wall, interven-
tricular septum and left ventricular end-diastolic dia-
meter in two-dimensional mode, according to the Penn
Convention. The formula of Devereux and Reichek
was used to estimate left ventricular mass [18]. Left
ventricular mass was divided by body surface area in
order to calculate left ventricular mass index.
Statistical analysis
Monitoring of data, data management and statistical
analysis of the results (SAS software package, Cary,
North Carolina, USA) were performed by an indepen-
dent agency (IMRO/Tramarko BV, Berghem, the
Netherlands). Results are recorded as mean  SD.
Analysis of variance was used to test for changes within
and differences between treatment groups. To test for
changes within and differences between treatment
groups after 1 and 2 years of treatment, repeated
measurement analysis of variance (RMANOVA) was
performed. The outcome variable was the change from
baseline IMT. The explanatory variables were treat-
ment and time as categorical main effects, and the
interaction treatment 3 time to allow for a differing
pattern of change in IMT between treatment groups. A
correction factor ‘statin treatment: yes/no’ as categorical
variable was implemented. Patients for whom there
were valid readings at baseline and at least one valid
observation after 1 and 2 years were included in this
RMANOVA. In the event of missing values, no imputa-
tion was allowed. Results are from intention-to-treat
analysis. Statistical tests were two-tailed; the level of
significance was set at 5%.
The effects of amlodipine and lisinopril on blood
pressure were tested by repeated measurement analysis
including all blood pressure measurements after the
start of treatment. The percentage of patients whose
blood pressure decreased to less than 140/90 mmHg
was calculated.
To study the relationship between changes in SBP,
DBP and pulse pressure and regression in IMT after
2 years of treatment, linear regression analyses was
performed with IMT regression as dependent variable,
and changes in blood pressure, median IMT at baseline
and time as independent variables. To study the
relationship between changes in left ventricular mass
index and regression of carotid and femoral IMT,
analyses of covariance were carried out, with change in
left ventricular mass index as dependent variable and
baseline left ventricular mass index, change in IMT
and time as independent variables.
The SD for the IMT was estimated from a repeatabil-
ity study. The paired absolute differences between the
first and the second series of IMT measurements were
calculated. The estimation of the SD was based on
these differences. The SD for the ‘maximum’ measure-
ments was 0.34. With 75 patients per treatment group,
a between-group difference of 0.06 mm is detectable
with a power of 90% for the maximum measurements.
This was considered a conservative estimate, because
for the final analysis repeated measure analysis was




In the population survey of two rural municipalities, a
total of 1969 inhabitants between 60 and 75 years of
age had their blood pressure measured. After three
serial blood pressure measurements, a total of 386
persons were considered to be previously untreated
hypertensive, and advised to take a salt-restricted diet.
After a period of 4 weeks of salt restriction, 191 patients
fulfilled the inclusion criteria and entered the ELVERA
trial. After a 2-week placebo run-in period, 166 patients
were allocated randomly to groups to receive amlodi-
pine or lisinopril. Baseline characteristics of these pa-
tients are given in Table 1. There were more male
patients in the lisinopril group than in the amlodipine
group (64% compared with 47%). The two groups did
not differ with respect to body mass index (patients
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1 Baseline characteristics of 166 patients allocated





Age (years) 67  4 67  4
Sex (M/F) 38/43 54/31
Body mass index (kg/m2) 28  3 28  4
DBP (mmHg) 92  8 93  9
SBP (mmHg) 175  15 175  14
Isolated systolic hypertension (n) 44 43
Smokers (%) 42 40
Left ventricular mass (g) 207  42 224  55
Total cholesterol (mmol/l) 6.0  1.0 5.8  0.9
HDL cholesterol (mmol/l) 1.2  0.3 1.3  0.3
LDL cholesterol (mmol/l) 4.0  0.9 3.9  0.8
Triglycerides (mmol/l) 1.8  1.1 1.4  0.6
Glucose (mmol/l) 4.9  1.9 4.6  1.2
Creatinine (mol/l) 84  13 88  18
Values are mean  SD or number. DBP, SBP, diastolic and systolic blood
pressures; HDL, LDL, high- and low-density lipoproteins.
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were mildly obese), blood pressure, age and lipid
profile.
In the amlodipine group, 16 patients had their dose of
medication reduced to 5 mg; in the lisinopril group,
seven patients had their dose of medication reduced to
10 mg, mainly because of adverse events. Of the 166
patients allocated randomly to the study groups, 120
completed the double-blind treatment phase. Patient
compliance judged by mean percentage of tablets taken
over 2 years of treatment was 83  6% for amlodipine
and 84  6% for lisinopril. Reasons for not completing
the study in the amlodipine group (n ¼ 24) were:
adverse events (14), withdrawal of informed consent
(six), violation of procedure (two), death (one) and
other (one). Reasons for not completing the study in
the lisinopril group (n ¼ 22) were: adverse events (11),
withdrawal of informed consent (four), violation of
procedure (four) and other (three).
Blood pressure measurements at baseline and at the
end of the study are shown in Table 2. Blood pressure
decreased significantly in both treatment groups
(P , 0.0001), with no differences between the groups.
The percentage of patients whose blood pressure de-
creased to less than 140/90 mmHg at the end of the
study did not differ between the groups: 26% in the
amlodipine group and 25% in the lisinopril group.
Baseline values for the combined mean maximum IMT
of the carotid and femoral arteries, and the changes in
the first year and the second year compared with the
first treatment year are shown in Table 3. After the first
year of treatment, there was a statistically significant
decrease in IMT in both treatment groups: 0.068 
0.097 mm in the amlodipine group and 0.035 
0.084 mm in the lisinopril group. During the second
year, a slight increase in IMT compared with that at
1 year was found in both treatment groups: 0.032 
0.107 mm in the amlodipine group and 0.009  0.107
mm in the lisinopril group (Table 3). A high baseline
value was associated with a more marked decrease in
IMT. The change in combined IMT from baseline for
‘amlodipine minus lisinopril’ was 0.024 [95% confi-
dence interval (CI) 0.059 to 0.011; P ¼ 0.18], indi-
cating no significant differences between the two
treatment regimens with respect to changes in IMT.
The maximum far wall IMT of the common carotid
artery and the common femoral artery are shown in
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 2 Blood pressure values at baseline and at the end of study
n Mean SD Median Minimum Maximum
Diastolic blood pressure (mmHg)
Amlodipine
Baseline 81 91.7 7.6 93.0 70.0 106.0
End of trial 72 83.3*** 6.2 82.0 66.0 100.0
Lisinopril
Baseline 85 93.0 9.0 94.0 70.0 115.0
End of trial 77 86.5*** 8.1 84.0 69.0 111.0
Systolic blood pressure (mmHg)
Amlodipine
Baseline 81 174.7 14.7 173.0 131.0 215.0
End of trial 72 148.2*** 16.2 148.5 106.0 191.0
Lisinopril
Baseline 85 174.6 14.1 172.0 140.0 220.0
End of trial 77 148.9*** 17.3 147.0 114.0 208.5
***Statistically significant difference compared with baseline (P , 0.0001).
Table 3 Combined maximum far wall intima–media thickness of carotid and femoral
segments
Combined maximum intima–media thickness (mm)
n Mean SD Median Minimum Maximum
Amlodipine
Baseline 71 1.210 0.281 1.153 0.736 2.224
Year 1 64 1.121*** 0.257 1.101 0.733 1.789
Year 2 63 1.166*** 0.236 1.163 0.828 1.756
Lisinopril
Baseline 77 1.194 0.282 1.124 0.795 2.212
Year 1 65 1.116*** 0.212 1.091 0.751 1.740
Year 2 63 1.129*** 0.232 1.084 0.751 1.698
***Statistically significant difference compared with baseline (P , 0.0001). No significant differences
between amlodipine and lisinopril were observed (P ¼ 0.18).
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Table 4. There was a significant treatment difference
between amlodipine and lisinopril in the common
carotid artery. Amlodipine was associated with a signifi-
cant reduction in IMT after 1 year of treatment, with a
slight increase after the second year of treatment,
whereas there was no significant reduction after treat-
ment with lisinopril (Fig. 1). This difference between
the two drugs in change from baseline in the common
carotid artery was 0.048 mm (95% CI 0.092 to
0.005 mm; P ¼ 0.03). In the common femoral artery,
both drugs showed a significant decrease in IMT after
1 year of treatment. After 2 years of treatment there
was a smaller increase in IMT, without restoration to
the baseline value, after lisinopril compared with that
produced by amlodipine, but this difference between
the drugs (0.023 mm; 95% CI 0.011 to 0.158 mm) was
not significant (P ¼ 0.73).
No significant relationships were found between regres-
sion in IMT and changes in DBP, SBP and pulse
pressure (R2 ¼ 0.005, P ¼ 0.25; R2 ¼ 0.002, P ¼ 0.50;
R2 ¼ 0.01, P ¼ 0.10, respectively).
There appeared to be no significant correlation be-
tween regression of left ventricular mass index and
regression of carotid and femoral IMT (R2 ¼ 0.002,
P ¼ 0.48; R2 ¼ 0.0004, P ¼ 0.74, respectively)
Discussion
In the ELVERA trial, both amlodipine and lisinopril
reduced combined carotid and femoral IMT to a similar
extent in elderly persons with mild to moderate hyper-
tension. The greatest reduction in IMT in our study
was observed after 1 year of treatment. Moreover, the
greatest reduction was found in those arterial segments
with the greatest baseline value, as seen in the femoral
artery. The reduction in IMT after 1 year was probably
mainly a result of the reduction in blood pressure,
although a significant relationship between reduction in
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 4 Far wall maximum intima–media thickness in common carotid artery and
common femoral artery
Intima–media thickness (mm)
n Mean SD Median Minimum Maximum
Common carotid artery (mm)
Amlodipine
Baseline 71 1.019 0.159 1.001 0.647 1.492
Year 1 64 0.971† 0.177 0.945 0.676 1.867
Year 2 63 0.986† 0.199 0.934 0.708 1.940
Lisinopril
Baseline 77 1.057 0.177 1.023 0.722 1.588
Year 1 65 1.054 0.201 0.982 0.760 1.892
Year 2 63 1.057 0.175 1.029 0.705 1.504
Common femoral artery (mm)
Amlodipine
Baseline 68 1.443 0.549 1.337 0.655 2.770
Year 1 63 1.333* 0.639 1.070 0.540 3.177
Year 2 63 1.496 0.616 1.361 0.693 3.050
Lisinopril
Baseline 72 1.502 0.621 1.370 0.651 3.157
Year 1 62 1.333* 0.632 1.061 0.664 3.648
Year 2 60 1.394 0.631 1.132 0.656 3.030
Statistically significant differences (P , 0.05) compared with: *baseline; †lisinopril. In the common femoral



























Effects of amlodipine (h) and lisinopril (n) on maximum intima–media
thickness of the far wall common carotid artery (CCA). CI, confidence
interval. *Statistically significant compared with change from baseline in
the lisinopril group (P , 0.05).
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blood pressure and decrease in IMT could not be
established. It is unlikely that the regression of IMT
was the result of regression of the mean, as we used up
to 10 measurements of IMT to obtain the maximum
IMT as the primary endpoint. Moreover, IMT was not
a selection criterion for the study. In addition, the
accuracy and reproducibility of dummy images were
checked regularly and the reproducibility of IMT
measurements was well within the acceptable range
[19]. After the first year of treatment, a slight increase
in IMT was observed in both treatment arms. It is
reasonable to believe that this reflects the effect of
ageing, because in placebo-controlled studies the rate
of progression of IMT varied between 0.006 and
0.030 mm/year [20,21]. We have previously reported a
significant reduction in left ventricular mass after 1 year
of treatment, with an even further reduction after the
second year of treatment [17]. This discrepancy in
increase in IMT and reduction in left ventricular mass
after the second year of treatment might explain why
we could not find a significant relationship between
reduction in IMT and reduction in left ventricular
mass.
Comparing carotid and femoral arteries, we found that
amlodipine had an effect on the elastic common carotid
artery, whereas lisinopril did not. In the muscular
femoral artery, both drugs were effective. Although the
results suggest a trend that lisinopril has a greater long-
term effect on the femoral artery than has amlodipine,
the differences were not significant.
The findings of a study by Stanton et al. [22] support
the observed greater reduction in common carotid IMT
after 1 year of treatment by amlodipine compared with
lisinopril in 69 previously untreated hypertensive pa-
tients. After 1 year of treatment, the mean regression
for the common carotid artery was 0.048 mm in the
amlodipine group, compared with 0.027 mm in the
lisinopril group (P ¼ 0.04). In contrast with our mono-
therapy study, doxazosin and bendrofluazide were
added to the treatment regimen if blood pressure
remained greater than 140/90 mmHg. When results
from all three carotid arterial segments were pooled for
the calculations, no significant difference between
amlodipine and lisinopril was observed. Therefore, it
seems that both drugs have the same effect on athero-
sclerosis-prone arterial segments, and possibly different
effects on segments that are not susceptible to athero-
sclerosis.
Our findings are also in line with the findings of the
Verapamil-Hypertension Atherosclerosis Study, in
which the calcium channel blocker verapamil reduced
carotid lesions after 4 years of treatment [23]. Similar to
our findings, the largest reduction in IMT was seen in
arterial walls with the greatest baseline values. Another
study that gives partial support to our findings is the
Prospective Randomized Evaluation of the Vascular
Effects of Norvasc Trial (PREVENT), in which the
effects of amlodipine on carotid IMT were studied in
comparison with placebo in patients with angiographi-
cally documented coronary artery disease. Amlodipine
significantly reduced carotid IMT, leading to a
0.0126 mm decrease after 3 years of treatment [24].
This reduction in IMT is much smaller than that
achieved in our study, but patients in PREVENT were
normotensive and the majority were receiving antihy-
pertensive drugs at baseline. There was no treatment
difference in the rates of all-cause mortality or major
cardiovascular events, although amlodipine use was
associated with fewer cases of unstable angina and
coronary revascularization. The International Nifedi-
pine Study on Intervention as a Goal in Hypertension
Treatment (INSIGHT) study showed that another
calcium antagonist, nifedipine, significantly slowed the
rate of progression of IMT compared with the diuretic
co-amilozide, whereas blood pressure reductions were
similar [25]. Another study showed that nifedipine
treatment inhibited IMT progression as early as after
26 weeks of treatment in previously untreated hyper-
tensive individuals [26]. Recently, the European Laci-
dipine Study on Atherosclerosis showed that the
calcium antagonist, lacidipine, had a greater efficacy
with respect to carotid IMT progression and number of
plaques per patient when compared with the -blocker
atenolol after 4 years of treatment [27].
It has been shown that nifedipine improves endothelial
function in patients with hypercholesterolaemia, inde-
pendent of the effect on blood pressure or plasma lipids
[28]. This effect of nifedipine is believed to be caused
by the enhancement of the bioavailability of endothe-
lial nitric oxide, possibly via an antioxidative protection
mechanism [28], which might contribute to the antith-
rombotic, antiproliferative, and anti-atherosclerotic ef-
fects of this dihydropyridine calcium antagonist.
With regard to the effects of ACE inhibitors on IMT,
the findings of clinical trials published to date are not
conclusive. In the Study to Evaluate Carotid Ultra-
sound Changes in Patients Treated with Ramipril and
Vitamin E, the effects on carotid IMT of 2.5 and 10 mg
ramipril compared with placebo were studied in a group
of 732 patients, aged 55 years or older, with vascular
disease or diabetes and at least one other risk factor
[29]. A significant beneficial effect of ramipril on the
progression of atherosclerosis was observed after
4.5 years of treatment. The reported progression slope
of the mean maximum carotid IMT in the placebo
group was 0.0217  0.0027 mm/year, whereas in the 2.5
and 10 mg ramipril groups, progression slopes of
0.0180  0.0026 and 0.0137  0.0024 mm/year, respec-
tively, were observed. Whether or not dose-dependent
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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ACE inhibition affects IMT remains unresolved. It
should be noted that about 33% of patients were
treated with lipid-decreasing drugs, equally divided
over the three treatment groups. In the Prevention of
Atherosclerosis with Ramipril Trial, the effect of rami-
pril on carotid atherosclerosis was studied in 617 pa-
tients with coronary, cerebrovascular or peripheral
vascular disease after 4 years of treatment [30]. In this
study, blood pressure and left ventricular mass were
significantly reduced after 4 years of treatment, but
there was no difference between placebo and ramipril
in the change in common carotid artery wall thickness
and carotid plaque.
One might object that our IMT measurements were
not corrected for possible differential effects of the two
antihypertensive drugs on changes in diameter in the
carotid artery. For several classes of antihypertensive
agents, including calcium antagonists and ACE inhibi-
tors, decreases in the carotid diameter have been
reported after the start of treatment. Such a decrease in
diameter may result in an increase in the IMT and thus
might mask a reduction in IMT in the progression of
atherosclerosis: in the INSIGHT study, a decrease of
1.2% in carotid lumen diameter was found for nifedi-
pine, which was not significantly different from the
2.5% decrease in the co-amilozide group. For lisinopril
and other ACE inhibitors, a comparable decrease in
carotid diameters has been reported. Although we
cannot exclude small effects of different changes in
carotid diameter, it is very unlikely that this would
have masked a difference in change in IMT between
amlodipine and lisinopril. The relatively small contri-
bution of changes in carotid diameter to changes in
IMT has been reported previously [31,32]. Moreover,
such effects on carotid diameter occur early after drug
initiation (when pressure is reduced) and remain rela-
tively stable without progression as the IMT changes,
suggesting that they did not confound IMT progression
over time. The fact that similar trends for amlodipine
and lisinopril were observed in the IMT over longer
periods of time in our study also makes it unlikely that
changes in carotid diameter have obscured differences
between the effects of the drugs on IMT.
Whether our observed decrease in IMT was the result
of functional vasodilatation rather than structural
changes remains unclear. Ultrasound imaging cannot
discriminate between the intimal layer and the medial
layer of the vessel wall in order to distinguish between
true atherosclerosis viewed as a disorder restricted to
the intimal layer and the adaptive response of the
medial layer to changes in tensile stress such as occur
during hypertension [33]. However, in contrast to the
carotid bifurcation, the common carotid artery is usually
relatively unaffected by atherosclerosis [33]. Taking
this into consideration, the larger reduction in IMT in
the common carotid artery segment in response to the
calcium channel antagonist might suggest an effect on
the medial layer as a result of a diminished tensile
stress. The reason why amlodipine leads to a greater
effect than lisinopril on the carotid artery but not on
the femoral artery remains to be explained. The carotid
artery is mainly an elastic artery, whereas the femoral
artery is mainly a muscular one. This might imply that
ACE inhibitors and calcium channel blockers have
different effects on elastic and muscular arteries. Con-
versely, common carotid artery far wall IMT is seen as
a marker of arterial wall hypertrophy and not of
atherosclerosis, because at this site intrusive plaques
are generally absent. In contrast, combined carotid and
femoral IMT, in addition to femoral IMT alone, are
markers of atherosclerosis because of the high fre-
quency of plaques at these sites. One explanation of
the observed differences between the effects of the
two drugs on common carotid artery IMT might be a
difference in local pulse pressure, as suggested by the
findings of a study by Boutouyre et al. [34], who
hypothesized that the reduction in carotid IMT is
mainly the result of a reduction in local pulse pressure.
Although the effect of amlodipine and lisinopril on
pulse pressure was not different in our study, we did
not measure local carotid pulse pressure. The majority
of our elderly patients with hypertension had systolic
hypertension. The use of calcium channel blockers is
favoured in patients with systolic hypertension [35].
Whether the fact that amlodipine, but not lisinopril,
produced a reduction in IMT in the common carotid
artery may be considered as an advantage of the
calcium channel antagonist over an ACE inhibitor in
patients with systolic hypertension remains to be in-
vestigated.
In conclusion, the calcium channel blocker amlodipine
and the ACE inhibitor lisinopril had similar effects on
the combined IMT of the carotid and femoral arteries
in these previously untreated, elderly patients with
hypertensivon after 2 years of treatment. Different
intervention effects of calcium channel antagonists and
ACE inhibitors in various parts of the arterial tree were
present, with differential effects of treatment on arterial
segments that are not susceptible to atherosclerosis.
Further studies are needed to clarify the real signifi-
cance of the observed differences in effects of the two
drugs on these latter arterial segments in hypertensive
patients.
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